ArticleTobacco induced diseases2026
The association of tobacco use on gastrointestinal cancers: A secondary dataset analysis of the Global Burden of Disease Study 2021 and Mendelian randomization.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastrointestinal cancers remain a major global health issue, with tobacco use as a key factor. Understanding the impact of tobacco use on these cancers and its regional trends is essential for effective prevention strategies.
methodsUsing data from the Global Burden of Disease (GBD) study, we analyzed mortality and disability-adjusted life years (DALYs) related to tobacco from 1990 to 2021. Joinpoint regression estimated average annual percent change (AAPC), and ARIMA predicted disease burden up to 2036. Two-sample Mendelian randomization (MR) analysis with GWAS data, applied methods such as inverse variance weighting (IVW) and MR-Egger for causal inference.
resultsEsophageal cancer had the highest burden in 2021, with a mortality rate of 2.54 deaths per 100000 population and a DALY rate of 58.49 DALYs per 100000 population. Stomach cancer showed the most significant decrease, with mortality dropping from 2.81 to 1.25 deaths per 100000 population (AAPC= -2.58; 95% uncertainty interval, UI: -2.61- -2.55) and DALY rates decreasing from 71.71 to 29.01 DALYs per 100000 population (AAPC= -2.87; 95% UI: -2.90 - -2.84). The disease burden was higher in older males. ARIMA analysis showed a general decline in disease burden, though some regions had an increasing trend. MR analysis did not provide genetic evidence supporting an association between tobacco use and these cancers.
conclusionsFrom 1990 to 2021, the global burden of gastrointestinal cancers linked to tobacco use showed a declining trend. However, mortality and DALY rates remain high, with significant regional, age, and gender differences, highlighting the need for continued tobacco control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.